mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant

Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Helen Parry, Gokhan Tut, Rachel Bruton, Sian Faustini, Christine Stephens, Philip Saunders, Christopher Bentley, Katherine Hilyard, Kevin Brown, Gayatri Amirthalingam, Sue Charlton, Stephanie Leung, Emily Chiplin, Naomi S Coombes, Kevin R Bewley, Elizabeth J Penn, Cathy Rowe, Ashley Otter, Rosie Watts, Silvia D'Arcangelo, Bassam Hallis, Andrew Makin, Alex Richter, Jianmin Zuo, Paul Moss
Formato:	article
Lenguaje:	EN
Publicado:	eLife Sciences Publications Ltd 2021
Materias:	COVID-19 vaccination immunosenescence Medicine R Science Q Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/f03f1cad0695471492d26dc7d9bac0ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant

Ejemplares similares